With every passing day, new discoveries are made that lend support to the increasing and important role biomarker analysis and tumor profiling play in personalized cancer care. Caris Life Sciences® is actively participating in research to advance the understanding of molecular science, further enabling the delivery of precision medicine.

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large

DICER1 mutations are associated with diverse and frequently histologically mixed-type malignancies in young and adult patients

Molecular Variations in Uterine Carcinosarcomas, Are There Therapeutic Opportunities

Mutational burden, tumor PDL‐1 expression, and microsatellite instability in gynecologic malignancies. Implications for immune therapy

Immune checkpoint expression, microsatellite instability, and mutational burden. Identifying biomarker phenotypes in uterine cancer

Distinct molecular profiles and potential therapeutic targets in androgen receptor stratified ovarian cancer patients

Treatment Choices Based on Multiplatform Profiling Platform, Unlike Those With Sequencing Alone, Do Not Cause a Cost Explosion in Refractory Cancer Patients

Multiplatform Tumor Profiling Delivers Value Bases Health Care in Refractory Cancer Patients

Comparison of Utility Cost in Three Commercially Available Precision Medicine Approaches in Oncology

Poly-ligand profiling differentiates trastuzumab treated breast cancer patients according to their outcomes